Idiopathic Generalized Epilepsy
5
0
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
20.0%
1 terminated out of 5 trials
66.7%
-19.8% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Blinking and Yawning in Epilepsy: The Role of Dopamine
RNS System NAUTILUS Study
Human Epilepsy Project 3
Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy